Biopharmaceutical company AbbVie Co. (ABBV) announced Tuesday that the U.S. Food and Drug Administration (FDA) will review a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) in combination with rituximab for the treatment of Waldenström's macroglobulinemia (WM), a rare and incurable type of non-Hodgkin's lymphoma (NHL).
from RTT - Biotech https://ift.tt/3eqZfLz
via IFTTT
No comments:
Post a Comment